OPKO Health (OPK)
(Real Time Quote from BATS)
$1.20 USD
-0.03 (-2.44%)
Updated Apr 25, 2024 01:40 PM ET
4-Sell of 5 4
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
OPK 1.20 -0.03(-2.44%)
Will OPK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for OPK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OPK
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
OPK: What are Zacks experts saying now?
Zacks Private Portfolio Services
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say
Other News for OPK
Commit To Buy OPKO Health At $1, Earn 15.2% Annualized Using Options
Notable open interest changes for April 11th
Notable open interest changes for April 10th
Largest borrow rate increases among liquid names
Opko Health Buy Rating Backed by Strategic Asset Sale and Promising Oral Drug Candidate